Irinotecan and Capecitabine Combination Chemotherapy in a Patient with Triple-negative Breast Cancer Relapsed after Adjuvant Chemotherapy with Anthracycline and Taxane

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

(2013) Iben Kümler et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer

(2012) Keun Seok Lee et al.   INVESTIGATIONAL NEW DRUGS

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis

(2012) MIAO LIU et al.   Oncology Letters

p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features

(2011) E. Biganzoli et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of Axillary Lymph Node Metastases (ALNM) in a Korean Population with T1-2 Breast Carcinoma: Triple Negative Breast Cancer has a High Incidence of ALNM Irrespective of the Tumor Size

(2010) Jong Hoon Lee et al.   Cancer Research and Treatment

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

(2009) W. W. Tan et al.   ANNALS OF ONCOLOGY